Annual report
4539.TEDINET S100VWWK
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥30.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥31.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥32.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥606m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | −¥494m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥443m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥219m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥58m | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥582m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥253m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥202m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥294m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥180m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥339m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥700m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥495m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥294m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | −¥180m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥49.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥48.6bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥49.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥47.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥30.7bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥31.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥19.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥18.0bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥296m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥916m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥394m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥35m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥305m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥144m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥793m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥29m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥81.72 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-50.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.07 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.33 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,312.46 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,116.02 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,130.65 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,119.99 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,006.49 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 38.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -1.0% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 855 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 887 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 872 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 809 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 760 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥23.5bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥22.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥22.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥86m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥339m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥983m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥690m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥149m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥984m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥143m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥777m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥349m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥249m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥643m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥33.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥34.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥35.9bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥35.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥34.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥23.6bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥25.5bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥9.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.3bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥11.0bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥11.1bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥39.33 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-212.84 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-95.59 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.32 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥176.96 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥50 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,581.63 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,570.03 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,802.53 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,004.58 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,034.03 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -7.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -3.3% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,261,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 330 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 352 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 349 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 347 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 352 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥89m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥62m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 75 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥79m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥99m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥86m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥86m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥6.4bn |
| Medicinereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.9bn |
| Medicinereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Medicinereportable segment | employees | at 2025-03-31 | 746 pure |
| Medicinereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥31.4bn |
| Medicinereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥31.4bn |
| Medicinereportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥7m |
| Medicinereportable segment | segment assets | at 2025-03-31 | ¥41.6bn |
| Medicinereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥506m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥32.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥32.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥43.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥606m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥9m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥106m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥18m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥18m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥9.2bn |
| Medicinereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Medicinereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Medicinereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥29.6bn |
| Medicinereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥29.6bn |
| Medicinereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥9m |
| Medicinereportable segment | segment assets | at 2024-03-31 | ¥38.4bn |
| Medicinereportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥600m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥30.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥30.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥18m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥40.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | −¥494m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 1 pure |
| Medicinereportable segment | employees | at 2025-03-31 | 295 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,641
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row7Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row8Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding revaluation of land for business (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of contract liabilities (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding financial covenant (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes derivatives consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes share options etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes real estate for lease etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration | Text · Plus | |
| Explanation of measurements of sales profit loss asset liability and other items for each reportable segment (text) | CurrentYearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |